Clinical Trial Update: A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial update for lirentelimab (AK002) in active eosinophilic esophagitis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• lirentelimab (lirentelimab)

Snippet

Sponsor: Allakos Inc. | Conditions: Eosinophilic Esophagitis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-01-02